Zynerba Pharmaceuticals Inc  

(Public, NASDAQ:ZYNE)   Watch this stock  
Find more results for ZYNE
-0.05 (-0.23%)
Real-time:   12:29PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.30 - 22.42
52 week 5.54 - 23.75
Open 22.27
Vol / Avg. 195,242.00/563,168.00
Mkt cap 283.48M
P/E     -
Div/yield     -
EPS -2.47
Shares 12.79M
Beta     -
Inst. own 17%
Mar 13, 2017
Q4 2016 Zynerba Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Dec 15, 2016
Zynerba Pharmaceuticals 2016 Clinical Research Day
Nov 30, 2016
Zynerba Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -4500.31%
Operating margin - -4493.06%
EBITD margin - -4483.73%
Return on average assets -66.55% -45.43%
Return on average equity -77.82% -79.30%
Employees 10 -
CDP Score - -


80 W. Lancaster Avenue, Suite 300
DEVON, PA 19333
United States - Map
+1-484-5817505 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.

Officers and directors

Armando Anido Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Terri B. Sebree President
Bio & Compensation  - Reuters
James E. Fickenscher Chief Financial Officer, Vice President - Corporate Development
Age: 52
Bio & Compensation  - Reuters
Suzanne M Hanlon Vice President - Human Resources, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Brian Boyd Vice President - Manufacturing
Bio & Compensation  - Reuters
Nancy Tich Ph.D. Vice President - Clinical
Bio & Compensation  - Reuters
Warren D. Cooper M.D. Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
William J. Federici Director
Age: 56
Bio & Compensation  - Reuters
Thomas L. Harrison Director
Age: 67
Bio & Compensation  - Reuters
Daniel L. Kisner M.D. Director
Age: 68
Bio & Compensation  - Reuters